LDL cholesterol goals are numbers again. The 2026 dyslipidemia guideline, issued on 13 March 2026 by the American College of Cardiology, the American Heart Association and nine other societies, restored specific target values that the 2013 and 2018 versions had deliberately dropped.[1]
Four months later a JAMA analysis measured what that change means in practice. Roughly one in three US adults without heart disease already sit above the new targets, and almost four in five of those who have already had a cardiac event do.[3]
LDL cholesterol goals, and the numbers the guideline now names
For someone at borderline or intermediate risk who has never had a cardiac event, the LDL-C goal is under 100 mg/dL. For those at high risk it drops to under 70 mg/dL.[1]
People who already have atherosclerotic cardiovascular disease and are judged very high risk get the strictest target: under 55 mg/dL. Non-HDL-C goals return alongside these, set roughly 30 mg/dL above each LDL-C figure.[1]
The reasoning is cumulative exposure. Guideline chair Roger Blumenthal put it plainly: lower LDL for longer, like lower blood pressure for longer, buys much greater protection against a future heart attack or stroke.[2]
Why the risk calculator changed who qualifies
The guideline replaces the old Pooled Cohort Equations with PREVENT-ASCVD, built for adults aged 30 to 79 with LDL-C between 70 and 189 mg/dL.[1]
This matters because the old equations overestimated ten-year risk by 40 to 50 per cent. PREVENT also reports a 30-year estimate, which shifts the conversation for people in their thirties and forties.[2]
Risk bands are now low (under 3 per cent), borderline (3 to under 5), intermediate (5 to under 10) and high (10 per cent or more). Those bands drive both whether to start a statin and how hard to push.[1]
Two tests the guideline wants measured at least once
Lp(a) should be checked once in adulthood. A level of 125 nmol/L or higher carries roughly a 1.4-fold long-term risk increase; at 250 nmol/L the risk at least doubles.[2]
Because Lp(a) is largely genetic and barely responds to lifestyle, repeat testing is not usually needed. ApoB is reserved for people with diabetes, kidney-metabolic syndrome, high triglycerides or known heart disease who have already hit their LDL-C goal.[1]
How far most people are from the target
The JAMA team applied the new goals to national survey data from 2021 to 2023, covering about 2,300 adults aged 30 to 79. Among the 39.1 million adults already on lipid-lowering therapy with a clear indication, 79.0 per cent were above goal.[3]
Within the group who had established cardiovascular disease, 91.1 per cent sat at or above 55 mg/dL and 74.5 per cent at or above 70 mg/dL. The Mass General Brigham team also found that roughly three in four of those newly eligible were on no treatment at all.[4]
What happens when a statin is not enough
Statins remain the foundation. When they fall short, the guideline lists ezetimibe, bempedoic acid and injectable PCSK9 antibodies as evidence-based add-ons, chosen by risk level and patient circumstances.[1]
Inclisiran, a less frequently injected option, is still in outcome trials. It lowers LDL-C, but whether that translates into fewer cardiac events has not yet been shown.[1]
Lifestyle is still the first move, not a formality. Weight, activity, tobacco and sleep all sit in the recommendation, and Blumenthal noted that 80 per cent or more of cardiovascular disease is preventable.[2] Diet quality matters here too, including the fats you cook with.
Limitations worth keeping in view
A guideline is a policy document, not a trial result. Setting lower targets expands the treated population, and whether treating those additional people yields net benefit at the population level has not been tested directly.
The JAMA prevalence estimate rests on a survey sample of about 2,300 people, weighted to represent the country, so the headline figures carry statistical uncertainty. It also describes a gap, not what closing it would achieve.[3]
These are US recommendations. Korean, European and Japanese societies set their own thresholds, and local risk equations are calibrated to local populations. Numbers here should be read alongside a local clinician, not instead of one.
| Aspect | Finding |
|---|---|
| LDL-C goal, primary prevention | Under 100 mg/dL at borderline or intermediate risk; under 70 mg/dL at high risk |
| LDL-C goal, secondary prevention | Under 55 mg/dL for people with ASCVD judged very high risk |
| Risk tool | PREVENT-ASCVD, ages 30–79, LDL-C 70–189 mg/dL, 10- and 30-year estimates |
| Old tool error | Pooled Cohort Equations overestimated 10-year risk by 40–50% |
| Lp(a) threshold | 125 nmol/L or higher ≈ 1.4× long-term risk; 250 nmol/L ≥ 2× |
| Adults above goal | About 1 in 3 without CVD; 79.0% of those already on therapy |
| CAC scan | Men 40+, women 45+ at borderline or intermediate risk; any calcium supports an LDL-C goal under 100 mg/dL |
| Child screening | All children aged 9–11 not previously screened |
References
- 2026 ACC/AHA Multisociety Guideline on the Management of Dyslipidemia, JACC and Circulation, 13 March 2026
- ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol, American Heart Association Newsroom, 13 March 2026
- Abohashem S et al., Prevalence of LDL-C Above 2026 Dyslipidemia Guideline Goals Among US Adults, JAMA, 20 July 2026
- Study Finds 1 in 3 Americans Without Heart Disease Miss New Cholesterol Goals, Mass General Brigham, July 2026
